View Older Stories View More Recent Stories

Jul 23, 2019 06:45AM Merck and Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment
Jul 22, 2019 04:30PM Sure Petcare Launches SureFeed® Microchip Pet Feeder Connect
Jul 18, 2019 08:00AM MilliporeSigma and Broad Institute Announce CRISPR License Framework to Encourage Innovation
Jul 17, 2019 06:48AM Merck (MRK) Announces FDA Approves its RECARBRIO for Treatment of Adults with cUTI and Complicated Intra-Abdominal Bacterial Infections
Jul 17, 2019 06:45AM FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited
Jul 10, 2019 06:45AM Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019
Jul 9, 2019 06:46AM Merck (MRK) Announces FDA Accepts its sBLA for KEYTRUDA Six-Week Dosing Schedule for Melanoma and Multiple Other Indications
Jul 9, 2019 06:45AM FDA Accepts Merck’s Supplemental Biologics License Applications for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule for Melanoma and Multiple Other Indications
Jul 1, 2019 06:45AM Merck to Hold Second-Quarter 2019 Sales and Earnings Conference Call on July 30
Jun 26, 2019 04:58PM Merck (MRK) Announces CDC ACIP Votes to Provisionally Recommend Shared Clinical Decision-Making for Vaccination of Adults Ages 27-45 with GARDASIL9 & Harmonization of Catch-up Vaccination
Jun 26, 2019 04:45PM CDC Advisory Committee on Immunization Practices (ACIP) Votes to Provisionally Recommend Shared Clinical Decision-Making for Vaccination of Adults Ages 27-45 with GARDASIL®9 & Harmonization of Ca
Jun 20, 2019 01:30PM Massachusetts-based Business Sectors of Merck KGaA, Darmstadt, Germany Named 'Best Places to Work' by Boston Business Journal
Jun 20, 2019 06:54AM Merck (MRK) Outlines Business Momentum, Strong Expected Growth
Jun 20, 2019 06:45AM Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
Jun 19, 2019 06:48AM AstraZeneca (AZN) and Merck's LYNPARZA Approved in Japan as First-Line Maintenance Therapy in Patients with BRCAm Advanced Ovarian Cancer
Jun 19, 2019 06:45AM AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer
Jun 18, 2019 06:47AM Merck (MRK) Announces FDA Approved its KEYTRUDA as Monotherapy for Some Patients with Metastatic SCLC with Disease Progression
Jun 18, 2019 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Leas
Jun 18, 2019 06:30AM LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer
Jun 13, 2019 08:14AM IBM (IBM), Merck (MRK), Walmart (WMT), KPMG to Collaborate with FDA on Pharma Product Integrity Protection Using Blockchain
Jun 13, 2019 08:05AM IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the use of blockchain to protect pharmaceutical product integrity
Jun 11, 2019 06:46AM Merck (MRK) Announces FDA Approved Two New Indications for KEYTRUDA
Jun 11, 2019 06:45AM FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)
Jun 10, 2019 06:45AM Merck (MRK) to Acquire Tilos Therapeutics for up to $773 Million
Jun 10, 2019 06:45AM Merck to Acquire Tilos Therapeutics
Jun 3, 2019 04:57PM Merck (MRK) Confirms FDA Approved its ZERBAXA 3g Dose for Treatment of Adults with HABP/VABP
Jun 3, 2019 04:55PM FDA Approves Merck’s ZERBAXA® (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Jun 3, 2019 04:19PM Merck's (MRK) LYNPARZA Phase 3 SOLO3 Trial Demonstrated 72% OR Rate in Patients with Platinum-Sensitive Relapsed gBRCAm
Jun 3, 2019 04:15PM LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patie
Jun 3, 2019 06:04AM Merck (MRK), AstraZeneca (AZN) Report Results from Phase 3 POLO trial evaluating LYNPARZA as First-Line Maintenance Therapy
Jun 2, 2019 07:30AM LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Ca
Jun 1, 2019 07:30AM Five-Year Survival Data for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting
May 31, 2019 06:48AM Merck's (MRK) KEYTRUDA (pembrolizumab) Demonstrates Improved OS at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial
May 31, 2019 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase
May 28, 2019 04:05PM Merck Announces Third-Quarter 2019 Dividend
May 21, 2019 06:50AM Merck (MRK) to Acquire Peloton Therapeutics for $1.05 Billion Upfront, Plus $1.15 Billion Contingent
May 21, 2019 06:45AM Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
May 20, 2019 04:32PM Merck (MRK) Phase 3 KEYNOTE-119 Study of KEYTRUDA Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer Doesn't Meet Primary Endpoint
May 20, 2019 04:30PM Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer
May 20, 2019 08:00AM MilliporeSigma Joins TRANSVAC2 Program to Advance Vaccine Development and Manufacturing
May 15, 2019 05:00PM New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting
May 14, 2019 07:44PM FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
May 9, 2019 07:00AM Katie Couric Joins Merck and Cancer Advocates to Support Patients and Caregivers Through the Expansion of Your Cancer Game Plan (YCGP)
May 8, 2019 09:01AM Merck (MRK) Reports Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants
May 8, 2019 09:00AM Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants
May 7, 2019 06:46AM Merck's (MRK) BELSOMRA C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for Treatment of Insomnia in People with Mild-to-Moderate Alzheimer’s Disease Dementia
May 7, 2019 06:45AM Merck’s BELSOMRA® (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer’s Disease Dementia
Apr 30, 2019 06:45AM Merck Announces First-Quarter 2019 Financial Results
Apr 29, 2019 06:45AM Merck (MRK) Announces LYNPARZA Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cance
Apr 29, 2019 06:45AM LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer
View More Recent Stories View Older Stories